Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Was the pain worth the gain? Antiretroviral savings from the ‘Improving value’ project and generics use in England

Laura Waters, Philip Aubrey, Janette Harper, Sarah Schoeman, Heather Leake Date, Lizzie Jordan, Peter Sharott, Tracy Palmer, Ian Harrison and Ian Williams
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.19-2-s76
Clin Med March 2019
Laura Waters
AGU/HIV Medicine, Mortimer Market Centre, Central and North West London NHS Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Aubrey
BNHS England, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janette Harper
BNHS England, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Schoeman
CGU/HIV Medicine, Leeds Teaching Hospitals NHS Trust, Leeds
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Leake Date
DGU/HIV Medicine, Brighton and Sussex University NHS Trust, Brighton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lizzie Jordan
EPatient Representative, NHS England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Sharott
BNHS England, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracy Palmer
FLondon commissioner, Specialised Services
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Harrison
BNHS England, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Williams
GInstitute for Global Health, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Aims

Antiretrovirals (ARVs) have transformed HIV prognosis; most individuals will take treatment lifelong and will enjoy a normal life expectancy. Based on 2015/6 ARV expenditure of £429 million in England, the HIV Clinical Reference Group (CRG) and NHS England (NHSE) developed an improving value (IV) scheme for ARVs. This identified a range of ARV switches aiming, where clinically appropriate and acceptable, to yield a 2.5% annual spending reduction over 2 years. Increasing availability of generic drugs also has the potential to reduce drug costs.

Methods

The HIV CRG, a multidisciplinary group including representatives from four England regions, community and specialty societies, developed a menu of switch choices and targets for implementation in 2016/7 and 2017/8, including patient information. Pharmacy submissions were analysed to estimate the impact of the IV project and like-for-like branded to generic switches on drug spend nationally and regionally. We present the impact of three IV switches and two generic switches for 2016/7.

Results

For the 2016/7 financial year, total ARV spend for England was £413.7 million, a 3.56% saving compared with 2015/6; savings ranged from 1.7% in the south to 5.0% in London. Thirty-three per cent of the savings were due to regional contract savings, 50% the nevirapine prolonged-release and abacavir/lamivudine generics substitutions and 17% the three analysed IV switches (equivalent to savings versus 2015/6 of 1.19%, 1.78% and 0.59%, respectively). The value of individual switches for England overall is summarised in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Value of antiretroviral switches

Focusing on combined savings secondary to only IV switches by region these were: £416,163 in the north, £247,929 in the south, £349,097 in midlands and east and £1,110,599 in London. Uptake of switches was high indicating acceptability to patients, and the importance of community engagement and support.

Conclusion

In England, ARV savings in 2016/7 exceeded the 2.5% target despite more people on treatment. In addition to significant savings secondary to regional contract negotiations and the ‘natural’ switch from branded drugs to generic equivalents, targeted changes of drug formulations, including changes in pill burden, can yield additional large ARV savings. In the current NHS climate we have a duty to work with patients to optimise prescribing efficiency but implementing appropriate, acceptable ARV switch strategies.

  • © Royal College of Physicians 2019. All rights reserved.
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Was the pain worth the gain? Antiretroviral savings from the ‘Improving value’ project and generics use in England
Laura Waters, Philip Aubrey, Janette Harper, Sarah Schoeman, Heather Leake Date, Lizzie Jordan, Peter Sharott, Tracy Palmer, Ian Harrison, Ian Williams
Clinical Medicine Mar 2019, 19 (Suppl 2) s76; DOI: 10.7861/clinmedicine.19-2-s76

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Was the pain worth the gain? Antiretroviral savings from the ‘Improving value’ project and generics use in England
Laura Waters, Philip Aubrey, Janette Harper, Sarah Schoeman, Heather Leake Date, Lizzie Jordan, Peter Sharott, Tracy Palmer, Ian Harrison, Ian Williams
Clinical Medicine Mar 2019, 19 (Suppl 2) s76; DOI: 10.7861/clinmedicine.19-2-s76
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Aims
    • Methods
    • Results
    • Conclusion
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Fracture Liaison Services in England and Wales, inequity of access and quality of care after a fragility fracture
  • The end of weak handover
  • Developing service delivery guidelines on acute medical emergencies: challenges and solutions
Show more Health Services and Policy

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians